
注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Selecta Biosciences Inc是一家临床阶段的生物制药公司。该公司利用其ImmTOR平台开发选择性缓解不必要免疫反应的耐受性疗法。它可以使挽救生命的基因疗法重新给药,并恢复自身免疫疾病的自我耐受。ImmTOR平台可减少抗药物抗体(ADA)的形成,并恢复自身免疫性疾病中自身抗原的自身耐受性。ImmTOR利用纳米颗粒技术将免疫调节药物雷帕霉素靶向抗原呈递细胞,在与相关抗原结合时产生抗原特异性免疫耐受。其纳米粒被设计为在注射到体内后保持完整,主要积聚在淋巴结、脾脏和肝脏中,在那里协调免疫反应。其候选产品SEL-212正处于III期临床开发阶段,包括聚乙二醇化尿酸酶pegadricase。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Carrie Smith Cox | 63 | 2019 | Independent Chairman |
Carsten Brunn | 50 | 2018 | CEO, President & Director |
Omid C. Farokhzad | 52 | 2007 | Member of Scientific Advisory Board |
Timothy A. Springer | 73 | 2008 | Independent Director & Member of Scientific Advisory Board |
Timothy C. Barabe | 68 | 2016 | Independent Director |
Aymeric Sallin | 47 | 2008 | Independent Director |
Scott D. Myers | 55 | 2019 | Independent Director |
Robert S. Langer | 72 | 2007 | Member of Scientific Advisory Board |
Patrick J. Zenner | 75 | 2017 | Independent Director |
Ulrich H. von Andrian-Werburg | - | 2007 | Co-Founder and Co-Chair of the Scientific Advisory Board |
Arlene Sharpe | - | - | Member of Scientific Advisory Board |
Nishan DeSilva | 50 | 2021 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核